{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:24:53Z","timestamp":1760189093436},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.3816\/clm.2009.n.084","type":"journal-article","created":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T02:02:24Z","timestamp":1262743344000},"page":"425-429","source":"Crossref","is-referenced-by-count":4,"title":["The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma"],"prefix":"10.3816","volume":"9","author":[{"given":"Paolo G.","family":"Gobbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Bonetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Dondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Falorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.n.084_bib1","first-page":"2704","article-title":"Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease","volume":"91","author":"Gobbi","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.084_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1158\/1078-0432.CCR-05-1707","article-title":"MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma. 10-year results, late toxicity and second tumors","volume":"12","author":"Gobbi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.n.084_bib3","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.3816\/CLM.2009.n.084_bib4","first-page":"455s","article-title":"Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherap, plus preplanned high-dose salvage, in advanced Hodgkin Lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups","volume":"26","author":"Gianni","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.084_bib5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD vs. BEACOPP vs. CEC for the initial treatment of patients with advanced Hodgkin lymphoma. Results from the HD2000 GISL Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.084_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","article-title":"Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP","volume":"36","author":"Bonadonna","year":"1975","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.n.084_bib7","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.084_bib8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3892\/or_00000320","article-title":"Bone marrow damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma","volume":"21","author":"Gobbi","year":"2009","journal-title":"Oncol Rep"},{"key":"10.3816\/CLM.2009.n.084_bib9","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1182\/blood.V83.12.3808.3808","article-title":"Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants","volume":"83","author":"Sutherland","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.084_bib10","series-title":"Statistical Methods in Medical Research","first-page":"408","author":"Armitage","year":"1987"},{"key":"10.3816\/CLM.2009.n.084_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2141.1996.00387.x","article-title":"Early suppressive effects of chemotherapy and cytokine treatment on committed versus promitive haemopoietic progenitors in patient bone marrow","volume":"92","author":"Schwartz","year":"1996","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.084_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.exphem.2006.12.006","article-title":"Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir","volume":"35","author":"Rocci","year":"2007","journal-title":"Exp Hematol"},{"key":"10.3816\/CLM.2009.n.084_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/BF02994004","article-title":"Chromosome and molecular abnormalities in myelodisplastic syndromes","volume":"73","author":"Fenaux","year":"2001","journal-title":"Int J Hematol"},{"key":"10.3816\/CLM.2009.n.084_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/bjc.1990.243","article-title":"The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function","volume":"62","author":"Radford","year":"1990","journal-title":"Br J Cancer"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T12:26:05Z","timestamp":1590495965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011700336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1557919011700336"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.n.084","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}